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Background and purpose: The performance of mammography screening programmes is focussed mainly
on breast cancer detection rates. However, when the benefits and risks of mammography are considered,
the risk of radiation-induced cancer is calculated for only the examined breast using Mean Glandular
Dose (MGD). The risk from radiation during mammography is often described as low or minimal. This
study aims to evaluate the effective lifetime risk from full field digital mammography (FFDM) for a
number of national screening programmes.
Material and Methods: Using an ATOM phantom, radiation doses to multiple organs were measured
during standard screening mammography. Sixteen FFDM machines were used and the effective lifetime
risk was calculated across the female lifespan for each machine. Once the risks were calculated using the
phantom, the total effective lifetime risk across 48 national screening programmes was then calculated;
this assumed that all these programmes use FFDM for screening.
Results: Large differences exist in effective lifetime risk, varying from 42.21 [39.12e45.30] cases/106
(mean [95% CI]) in the Maltese screening programme to 1099.67 [1019.25e1180.09] cases/106 for high
breast cancer risk women in the United States of America. These differences are mainly attributed to the
commencement age of screening mammography and the time interval between successive screens.
Conclusions: Effective risk should be considered as an additional parameter for the assessment of
screening mammography programme performance, especially for those programmes which recommend
an early onset and more frequent screening mammography.
© 2018 The College of Radiographers. Published by Elsevier Ltd. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Breast cancer is a major public health concern and is the most
frequently detected cancer among women in many countries.1 It is
the fifth largest cause of cancer death worldwide.2 In 2012, breast
cancer constituted 25% of new cancer cases in women and around
1.7 million new breast cancer cases were recorded worldwide.3
Breast cancer morbidity differs significantly between regions and
according to the American Cancer Society (ACS),3 39% of breastology Dept., Faculty of Medi-
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lished by Elsevier Ltd. This is ancancer cases were recorded in Asia while in Europe and North
America, the figures were 28% and 15%, respectively. Early diagnosis
and treatment of breast cancer is the key to reduce mortality.4
Randomised screening trials using mammography illustrated that
screening can reduce breast cancer mortality by 15e20%.5 Since
mammography is seen as a cost-effective technique for early
detection of breast cancer, it remains the recommended modality
for both screening and diagnosis.6
The performance of any screening programme should be
assessed by three parameters; sensitivity, specificity, and positive
predictive value.7,8 The calculation of these parameters depends on
three related quantities; mammography false negatives which
represents mammography's inability to detect all breast cancers,
mammography false positives which may result in extra exami-
nations and undesired anxiety for women, and overdiagnosis of
low risk breast cancers that may never cause health problems.9,10open access article under the CC BY-NC-ND license (http://creativecommons.org/
Table 2
Illustrates the recommendations of mammography screening programmes in
different countries for women with a high risk of breast cancer.15,16
Country(s) Age of
screening
Time interval
between screens
Number of
screens
Canada 40e74 1 year (40e49)
2 years (50e74)
23
United Kingdom 40e73 1 year 34
United States (ACS) 30e75 1 year 46
United States (NCCN) 25e75 1 year 51
R.M.K. M.Ali et al. / Radiography 24 (2018) 240e246 241The most suitable measure of screening mammography benefit is
the reduction in breast cancer mortality in women being screened
compared to that in unscreened women.11
The risk-benefit argument resulted in the introduction of
organised mammography screening programmes in many coun-
tries; though the recommendations for screening mammography
are different among them in regards to the age of screening
commencement and cessation age of the screens, and the time
interval between screens (Table 1).12
The screening categories in Table 1 are recommended for
average breast cancer risk women. High risk women include those
with personal or familial history of breast cancer, or withmutations
in breast cancer susceptibility genes BRCA1 and BRCA2, or with
high breast density. Some of the mammography screening pro-
grammes exclude the high risk women and consider them as spe-
cial cases, e.g. the Australian programme,14 while other
programmes have a specially designed screening category, e.g. the
United States (U.S) and the United Kingdom (U.K) programmes
which recommend early commencement annual mammography
(Table 2). However, these strategies will result in an additional risk
of cancer incidence due to radiation. Therefore some programmes
use another imaging modality for screening, for example ultra-
sound or magnetic resonance imaging in addition to screening
mammography.15
The risk of radiation-induced cancer from screening mammog-
raphy has been considered small17 and not included in the mor-
tality assessment of screening programmes. This may be due to lackTable 1
Illustrates the recommendations of mammography screening programmes in
different countries for women with an average risk of developing breast cancer.12,13
Country(s) Age of
screening
Time interval
between screens
Number
of screens
Australia, Japan, Korea,
United States (AAFP, NCI,
and USPSTF)a
40e75 2 years 18
Belgium, Croatia, Cyprus,
Denmark, Finland, Germany,
Italy, Latvia, Lithuania,
Luxembourg, Norway,
Poland, Slovenia, Spain
(Catalonia), Switzerland
50e69 2 years 10
Canada, France, Israel,
Netherlands
50e74 2 years 13
China 40e59 3 years 7
Czech 44e75 2 years 16
Estonia 50e62 2 years 7
Hungary 45e65 2 years 11
Iceland 40e69 2 years 15
India 40e74 1 year (40e49)
2 years (50e74)
23
Ireland 50e64 2 years 8
Malta 50e60 3 years 4
New Zealand, Portugal,
Spain (Navarra)
45e69 2 years 13
Nigeria 40e70 2 years 16
Sweden 40e74 18 months (40e49)
2 years (50e74)
19
United Kingdom 47e73 3 years 9
United States (ACOG)b 40e75 2 years (40e49)
1 year (50e75)
31
United States (ACS, ACR,
and NCCN)c
40e75 1 year 36
Uruguay 40e69 2 years (40e49)
1 year (50e69)
25
a American Academy of Family Physicians, National Cancer Institute, and US
Preventive Services Task Force.
b The American Congress of Obstetricians and Gynaecologist.
c American Cancer Society, American College of Radiology and National Cancer
Comprehensive Network.of availability of an accurate and reliable method to provide data
about this risk. Therefore, within this study, the recently published
method by M. Ali et al.18 was utilised to evaluate the radiation risk
from several national screening programmes using total effective
risk during a female's lifetime. An assumption was made that all
screening programmes would use FFDM for screening. The aim of
this work was, therefore, to assess the radiation risk from FFDM
screening for a number of national screening programmes.
Method
An experimental approach was used to measure organs' doses
using thermoluminescence dosimeters (TLDs) for standard four-
view screening mammography. To achieve this, an adult ATOM
dosimetry phantom and a bespoke breast phantom were used
(Fig. 1). The absorbed dose for critical organs was measured for
several different FFDM units. Dose data were used to calculate
lifetime effective risk (equation (2)).
To simulate a women's body, an adult ATOM dosimetry phan-
tom (CIRS Inc, Norfolk, Virginia, USA) was used. Within this phan-
tom, there are detector holes in 20 radiosensitive organs.
Manufacturer supplied breast attachments were used to simulate
contralateral breasts each with a grid of holes inside to accom-
modate the dosimeters.19Figure 1. ATOM and breast phantoms positioned on a FFDM machine in the cranio-
caudal (CC) position.
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ness of a standard simulated breast during screening mammog-
raphy. A polymethyl methacrylate (PMMA)-polyethylene (PE)
breast phantomwas utilised as described by Bouwman et al.20 This
phantom is composed of 32.5 mm PMMA and 20.5 mm PE resulting
in a total thickness of 53 mm which is the thickness of standard
breast in the craniocaudal (CC) position.20 However, as reported by
the International Atomic Energy Agency,21 the breast thickness in
the mediolateral oblique position (MLO) is more than that in CC
position by 5mm. Therefore, 32.5 mm PMMA and 25.5mm PEwere
used to simulate the standard breast in MLO position. Since the
radiation dose to an organ is likely to result from scattered radia-
tion, the breast phantom shape, area, and volume were of great
importance. Accordingly, two different breast phantoms were used
- one to simulate the breast in CC position which was semi-circular
with 95 mm diameter, and the other to simulate the standard
breast in MLO position which was a rectangular shape of 100 by
150 mm. In general, the breast phantom used in this work repre-
sents a simple model and may not be representative of typical
breast sizes and densities in different countries.
280 TLD-100H (Thermo Scientific, USA) were accommodated
inside the ATOM phantom to measure the radiation dose received
by body tissues and organs. Before use, TLDs underwent a process
of preparation which includes the determination of errors associ-
ated with their readings. These errors are mainly attributed to
differences in sensitivity and consistency between TLDs. The
method described by M.Ali et al.18 was utilised to assess these er-
rors. TLDs used in this experiment had a 4% total error, which is
within that accepted by the European Commission22 which rec-
ommends a maximum error of 10% in TLDs measurements.
Prior to use, all TLDs were annealed at 240 C for 10 min to
remove any residual stored energy. Three TLDs were used to
measure background radiation which was subtracted from the
reading of each TLD. To convert the TLDs' charge to equivalent ra-
diation absorbed dose, they were calibrated against a solid state
dosimeter (Multi-O-Meter, Unfors, Billdal, Sweden) using the same
beam quality from each mammographic machine that was utilised
for the phantom exposures.
The ATOM phantom, loaded with TLDs, and the breast phantom
were positioned on 16 FFDMmachines and exposed as per standard
screening mammography technique (CC and MLO for each breast)
using automatic exposure control (AEC) (Table 3). All the FFDM
machines were quality tested against standard NHSBSP protocolsTable 3
The sixteen FFDM machines used in this study with their recorded exposure factors.
Machine Number Site Machine Brand
1 A Hologic Selenia
2 B Hologic Selenia
3 C Hologic Selenia Dimensions
4 C Hologic Selenia
5 D GE Seno Essential
6 D GE Seno Essential
7 D Hologic Selenia Dimensions
8 D Giotto
9 E GE Seno Essential
10 E GE Seno Essential
11 E GE Seno Essential
12 F GE Seno Essential
13 G GE Seno Essential
14 G GE Seno Essential
15 H Siemens Mammomat Inspiration
16 H Siemens Mammomat Inspirationwhich incorporated IPEM quality control recommendations.23 In
order to minimise random error the breast phantom was exposed
three times in each position and mean dose values were obtained.
The 16 FFDM machines were located in eight hospitals within the
United Kingdom and no consideration was taken about the po-
tential of exposure factors variations between different countries.
The machines included GE, Hologic, Siemens and Giotto. To identify
each mammography machine and its site, each was given a unique
identification number from 1 to 16 (Table 3). For the first two
machines, the process was repeated on three separate occasions in
order to assess data reliability.
The organs dose, MGD and effective risk assessment were
calculated for each of the sixteen FFDM machines.
MGDwas calculated using Dance's equation (equation (1))24 and
as described by IPEM23 by multiplying breast phantom entrance air
kerma (without backscatter), measured using the solid state
dosimeter which was attached to the lower surface of the
compression paddle at a midpoint about 4 cm from the chest
wall,25 with conversion factors g53 and s. The g53 conversion factor
is used to convert the incident air kerma for the phantom to MGD
for standard breast and the s factor to correct for different target/
filter combinations. However, the glandularity conversion factor
(c53) was not used (considered equal to 1) because it is used for the
correction of MGD from the equivalent glandularity of the phantom
which is 29% to 50% glandularity breast. To illustrate, using this
factor means that the MGD is calculated for a 50% glandularity
breast while other organ doses were measured for a 29% glan-
dularity breast.
MGD ¼ K:g53:c53:s (1)
Effective risk, the number of cancer cases produced by the
exposure to X-ray, for each year of clients age from 25 to 75 was
calculated using Brenner's equation26 (equation (2)) and BEIR VII27
lifetime attributable risk factors. Since these factors are only
available for each decade of a women's age, they were plotted
against age to adjust for unpublished data for each year of life. In
this context, to minimise the error associated with the fitting pro-
cess, two graphs have been plotted for each type of tissue: one
graph for obtaining the risk for 20e29 inclusive and another one for
30e39, 40e49, 50e59, 60e69, and 70e79 inclusive. These steps
were undertaken because of the tissue radiosensitivity change
during 20e29 greatly differs from that of the other ages. Next, the
total effective lifetime risk for each identified screening programmeTarget/filter combination Exposure factors
CC MLO
kV mAs kV mAs
Mo/Mo 29 65 30 72
Rh/Rh 28 122 29 130
W/Rh 30 142 31 162
Rh/Rh 28 137 29 143
Rh/Rh 29 57 29 63
Rh/Rh 29 50 29 53
W/Rh 30 122 31 148
W/Ag 29 57 30 59
Rh/Rh 29 52 29 52
Rh/Rh 29 60 29 60
Rh/Rh 29 50 29 50
Rh/Rh 29 55 29 60
Rh/Rh 29 55 29 55
Rh/Rh 29 55 29 58
W/Rh 28 108 29 111
W/Rh 29 88 29 106
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risk from screening programmes with the number of screened
women in 2010 were used to calculate the predicted number of
cancer cases induced by radiation for each of the programmes,
again assuming that all of these programmes used FFDM for
screening.
R ¼
X
rTHT (2)
Where R is the effective risk, rT is the lifetime cancer risk for
tissue T per unit equivalent dose of that tissue, and HT is the
equivalent dose for tissue T.26Results
Data generated from reliability experiments are presented in
(Fig. 2) and (Fig. 3) for the first and second FFDM machines,
respectively.
The possible effect of measured dose variations on total effective
risk during female lifetime, for different mammography screening
programmes, for both first and second FFDM machines are pre-
sented in (Table 4).
Upon data review, it is evident that some organs did not receive
any radiation dose during screening mammography (Table 5).
However, other organs (other than examined breast) received a
radiation dose ranging from less than 1 mGy (e.g. oesophagus, heart
and stomach) to more than 25 mGy (contralateral breast).
Differences exist between screening programmes with regard to
total effective risk during a female's lifetime. The highest total
effective risk resulted from early commenced mammography
screening programmes especially those designed for high-risk
women who commence screening mammography younger than
30 years old (Table 6).
The predicted number of radiation-induced cancers from
different mammography screening programmes (Table 7)Figure 2. Organ dose variations (mean ± 1SD) measured for thhighlights that the highest number of radiation-induced cancers
would result from the screening programme in Korea because of
the high total effective risk which was 193.86 with CI 95% [179.67,
208.04] as well as the large number of participants (more than 2.5
million).
Discussion
Reliability study data using machines 1 and 2 (Figs. 2 and 3,
respectively) illustrate that there were some differences amongst
the measured organ doses across the three visits. These differences
may be attributable to the consistency of the AEC because different
exposure factors were recorded for the three visit/exposures. Also,
the random nature of the X-ray beam and some experimental er-
rors, such as that due to minor positioning alterations, may
contribute to these differences. However, these radiation dose dif-
ferences do not introduce appreciable differences in the calculated
total effective risk between the three experiments (Table 4). The
comparison of the sixteen FFDMmachines studied in relation to the
total effective risk shows some differences. For instance, for 10
biennial screens starting from age 50 to 69 years, the total effective
risk ranged from 59.23 (machine 11 which results in lowest risk) to
99.58 cases/106 (machine 7 which results in highest risk).
With regard to total effective risk, the number of radiation-
induced cancers, the comparison of different country based
mammography screening programmes showed that, if they all use
the same screening modality (FFDM) and 2 views (CC and MLO) for
each breast, the lowest total effective risk resulted from screening
programme in Malta, while the highest resulted from the U.S
screening programme for high-risk women (Table 6). For any
screening programme, the main factor which affects the total
effective risk is the commencement age of screening; as younger
tissues are more radiosensitive.33 For example, the total effective
risk resulting from the Chinese screening programme, which in-
vites the women 7 times for triennial screening mammographyree different visits/exposures for FFDM machine number 1.
Figure 3. Organ dose variations (mean ± 1SD) measured for three different visits/exposures for FFDM machine number 2.
Table 4
Highlights variations in total effective risk for a series of national screening pro-
grammes, which could result from the variations in organ doses as measured on
three visits/exposures for FFDM machines 1 and 2.
Programmea Total effective risk (case/106),
Mean (SDb) of the three visits
Machine 1 Machine 2
Malta 50.57 (0.05) 48.48 (0.04)
Estonia 77.40 (0.08) 74.20 (0.07)
Ireland 81.10 (0.09) 77.76 (0.07)
United Kingdom 84.75 (0.09) 81.27 (0.08)
Belgium, Croatia, Cyprus,
Denmark, Finland, Germany,
Italy, Latvia, Lithuania, Luxembourg,
Norway, Poland, Slovenia, Spain
(Catalonia), Switzerland
85.55 (0.10) 82.05 (0.08)
Canada, France, Israel, Netherlands 88.64 (0.11) 85.04 (0.10)
Hungary 142.63 (0.14) 136.70 (0.11)
New Zealand, Portugal, Spain (Navarra) 146.32 (0.15) 140.27 (0.12)
China 147.26 (0.13) 141.07 (0.09)
Czech 163.44 (0.17) 156.69 (0.14)
Iceland 229.20 (0.22) 219.63 (0.16)
Nigeria 230.46 (0.22) 220.84 (0.17)
Australia, Japan, Korea, United States
(AAFP, NCI, and USPSTF)
232.29 (0.23) 222.63 (0.17)
Sweden 270.71 (0.26) 259.42 (0.19)
Uruguay 305.88 (0.31) 293.18 (0.24)
United States (ACOG) 311.81 (0.33) 298.93 (0.26)
India 366.72 (0.35) 351.38 (0.25)
United States (ACS, ACR, and NCCN) 446.24 (0.45) 427.69 (0.34)
Canada 366.72 (0.35) 351.38 (0.25)
United Kingdom 444.46 (0.44) 425.97 (0.33)
United States (ACS) 942.16 (0.84) 902.53 (0.57)
United States (NCCN) 1318.68 (1.15) 1263.04 (0.74)
Screening programmes designed for high breast cancer risk women are highlighted
in grey.
a The programmes are ordered according to total effective risk.
b (SD) is the standard deviation.
Table 5
Lists organs radiation dose from one screening visit, mean [95% CI] for the sixteen
FFDM machines.
Organ Absorbed dose, mGy
Mean 95% CI
Brain 0.91 0.32e1.51
Salivary glands 2.79 2.33e3.25
Thyroid 9.45 7.96e10.95
Oesophagus 0.26 0.15e0.36
Thymus 2.43 1.82e3.03
Heart 0.39 0.28e0.50
Lung 3.06 2.54e3.58
Liver 0.69 0.55e0.83
Gall bladder 0.19 0.11e0.27
Adrenal 0.10 0.03e0.17
Kidney 0.05 0.03e0.07
Spleen 0.09 0.04e0.14
Pancreas 0.04 0.01e0.07
Stomach 0.42 0.32e0.53
Intestine 0.03 0.01e0.05
Bone Marrow (BM) Cranium (7.6%)a 1.56 0.88e2.25
Mandibles (0.8%)a 2.79 2.33e3.25
C-spine (3.9%)a 0.30 0.13e0.47
Clavicles (0.8%)a 9.25 6.68e11.82
Scapulae (2.8%)a 0.17 0.10e0.24
Sternum (3.1%)a 19.07 16.08e22.07
Ribs (16.1%)a 3.57 2.93e4.21
T/L spine (28.4%)a 0.07 0.04e0.09
Pelvis (27.4%)a 0.00 0.00e0.00
Total BM dose 1.42 1.22e1.62
Urinary bladder 0.00 0.00e0.00
Uterus 0.00 0.00e0.00
Ovaries 0.00 0.00e0.00
Contralateral breast 28.75 24.56e32.93
Examined breast (MGD) 2018.50 1871.34e2165.66
a These percentages represent the portion of bone marrow (BM) in different lo-
cations. They were adapted from ICRP report 70 (1995).28
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Table 6
Illustrates total effective risk (mean [95% CI] for the sixteen FFDM machines) for
different national screening programmes.
Programme Total effective risk (case/106)
Mean 95% CI
Malta 42.21 39.12e45.30
Estonia 64.62 59.89e69.35
Ireland 67.72 62.76e72.68
United Kingdom 70.77 65.59e75.95
Belgium, Croatia, Cyprus, Denmark,
Finland, Germany, Italy, Latvia,
Lithuania, Luxembourg, Norway,
Poland, Slovenia, Spain (Catalonia),
Switzerland
71.45 66.22e76.68
Canada, France, Israel, Netherlands 74.06 68.64e79.49
Hungary 119.04 110.33e127.75
New Zealand, Portugal, Spain (Navarra) 122.15 113.21e131.08
China 122.83 113.85e131.81
Czech 136.45 126.46e146.43
Iceland 191.25 177.26e205.24
Nigeria 192.30 178.24e206.37
Australia, Japan, Korea, United States
(AAFP, NCI, and USPSTF)
193.86 179.67e208.04
Sweden 225.89 209.37e242.42
Uruguay 255.30 236.62e273.98
United States (ACOG) 260.32 241.27e279.37
India 305.96 283.58e328.34
United States (ACS, ACR, and NCCN) 372.42 345.18e399.67
Canada 305.96 283.58e328.34
United Kingdom 370.92 343.79e398.06
United States (ACS) 785.82 728.35e843.30
United States (NCCN) 1099.67 1019.25e1180.09
Screening programmes designed for high breast cancer risk women are highlighted
in grey.
R.M.K. M.Ali et al. / Radiography 24 (2018) 240e246 245commencing at the age of 40 years, is higher than that produced by
U.K programme, which invites women from the age of 47 years for
triennial screening 9 times.
In our work, the total effective risk data are applicable to UK
based exposure factors and FFDM set-up parameters and average
sized women with a standard breast thickness (53 mm). With re-
gard to simulated breast density, the breast phantom simulated the
breast density of 29%. As recommend by Yaffe et al.,29 who studiedTable 7
The predicted number of radiation-induced cancer cases from screening mammography
Country(s) Number of Screened womena Total effect
Mean
Korea 2602928 193.86
Japan 2492868 193.86
Sweden 1414000 225.89
France 2343980 74.06
China 1200000 122.83
UK 1957124 70.77
Italy 1340311 71.45
Uruguay 352000 255.30
Netherlands 961766 74.06
Poland 985364 71.45
Spain Catalonia 527000 71.45
New Zealand 211922 122.15
Denmark 275000 71.45
Israel 220000 74.06
Canada 196187 74.06
Norway 199818 71.45
Portugal Central 100348 122.15
Spain Navarra 40016 122.15
Switzerland 60700 71.45
Iceland 20517 191.25
Luxembourg 14586 71.45
Portugal Alentejo 7298 122.15
a These numbers represent the participants for 2010 in different screening mammogrbreast composition in 2831 Canadian women, this glandularity
(29%) represents the most common breast density because 95% of
their study participants had a breast density of less than 45%.
Accordingly, calculations reported within our work are applicable
for common breast densities only.
Compared to previous studies, which considered the total life-
time attributable risk (LAR) of cancer incidence in breast tissue
only, the calculated total effective risk in our study, which includes
the risk of radiation-induced cancer in all body tissues, tends to be
comparable because the MGD contribution in total effective risk is
approximately 98%. In work by Yaffe and Mainprize30 the total risk
of radiation-induced breast cancer from annual screening
mammography between 40 and 49 years was found to be 159
cases/106/mGy. In our study the total effective risk for the same
screening regimen was found to be 114.85 [106.46e123.25] cases/
106/mGy (mean with 95% CI). Hendrick31 found that the total
incident of breast cancer due to annual screening mammography
between 25 and 80 years ranged between 551.35 and 702.70 cases/
106/mGy. In our work the calculated total effective risk for annual
screening mammography between 25 and 75 years was 544.66
[504.83e584.49] cases/106/mGy.
Recently, Warren, Dance, and Young32 evaluated the total risk,
during a female's lifetime, of radiation-induced breast cancer from
the UK screening recommendations and found that it ranged be-
tween 30.7 and 61.2 cases/106/mGy. This is consistent with data
presented in our study where 35.05 [32.49e37.62] cases/106/mGy
were reported. In general, the differences in total effective risk
between previously published articles and our study may be
attributed to different imaging techniques (image receptors) and/or
different risk models used to derive the LAR factors which were
used to calculate total effective risk. Compared to breast cancer
mortality reduction by screening mammography, this radiation risk
can be considered as extremely small but not zero. The results of
our study demonstrate that the previously published method by
M.Ali et al.18 can be considered suitable for the estimation of ra-
diation risk from screening mammography. This can be evidenced
by its ability to consider the risk of radiation-induced cancer for all
body tissues from screening mammography and for women of
different ages.in different countries for the sixteen studied machines.
ive risk (case/106) Number of cancer cases
95% CI Mean 95% CI
179.67e208.04 504.60 467.67e541.51
179.67e208.04 483.27 447.89e518.62
209.37e242.42 319.41 296.05e342.78
68.64e79.49 173.60 160.89e186.32
113.85e131.81 147.40 94.88e158.17
65.59e75.95 138.51 128.37e148.64
66.22e76.68 95.77 88.76e102.78
236.62e273.98 89.87 83.29e96.44
68.64e79.49 71.23 66.02e76.45
66.22e76.68 70.40 65.25e75.56
66.22e76.68 37.65 34.90e40.41
113.21e131.08 25.89 23.99e27.78
66.22e76.68 19.65 18.21e21.09
68.64e79.49 16.29 15.10e17.49
68.64e79.49 14.53 13.47e15.59
66.22e76.68 14.28 13.23e15.32
113.21e131.08 12.26 11.36e13.15
113.21e131.08 4.89 4.53e5.25
66.22e76.68 4.34 4.02e4.65
177.26e205.24 3.92 3.64e4.21
66.22e76.68 1.04 0.97e1.12
113.21e131.08 0.89 0.83e0.96
aphy programmes.12
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screening using FFDM, may be associated with a degree of error;
this error results from the fitting process of lifetime attributable
risk. Also, according to Alonzo-Proulx et al.,33 the volumetric breast
density (VBD) reduces by 2% per year as women age increased from
35 to 75 years. This reduction in breast density, not considered in
our phantom study, may result in minor overestimation of effective
risk and this should be considered within future work. Also, cancer
incidence varies between countries and even between women due
to genetic factors and these should be considered in future work.
Further work should also be undertaken in order to simulate a
range of breast sizes and densities, exposure factors and set-up
differences in different countries.Conclusion
The total effective risk should be considered for use as an
additional parameter for the assessment of screening mammog-
raphy programme performance, especially for those programmes
which recommend an early onset and more frequent screening
mammography. For total effective risk, the MGD contribution is
more than 98%, while all body tissues other than the examined
breast contribute up to 2%. Therefore, for any screening programme
the most important factors affecting the total effective risk are
screening commencement age, screening frequency and MGD.
Although the effective risk differences amongst the 16 FFDM ma-
chines are not significant statistically, the MGD variation of
different FFDM machines should be considered.References
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